(Reuters) -Mallinckrodt Pharmaceuticals and Endo are exploring a potential merger that could be valued at about $7 billion, Bloomberg News reported on Wednesday, citing people with knowledge of the matter.
The drugmakers are discussing the terms of a transaction that would give each of them roughly 50% ownership of the combined entity, the report said.
A deal could be struck as soon as this week and the combined company is expected to be listed on the New York Stock Exchange, according to the report.
Mallinckrodt and Endo did not immediately respond to Reuters requests for comment.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Arun Koyyur)
Comments